KRAS, NRAS and HRAS, referred to as oncogenic RAS, gained our attention from the viral carcinogenesis pathway, breast cancer pathway and renal cell carcinoma pathway (Fig. 2G, H). Here, KRAS is linked to hereditary clear cell renal cell carcinoma.